High-resolution analysis of long-term serum antibodies in humans following convalescence of SARS-CoV-2 infection.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 05 2022
31 05 2022
Historique:
received:
22
09
2021
accepted:
09
03
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
Long-term antibody responses to SARS-CoV-2 have focused on responses to full-length spike protein, specific domains within spike, or nucleoprotein. In this study, we used high-density peptide microarrays representing the complete proteome of SARS-CoV-2 to identify binding sites (epitopes) targeted by antibodies present in the blood of COVID-19 resolved cases at 5 months post-diagnosis. Compared to previous studies that evaluated epitope-specific responses early post-diagnosis (< 60 days), we found that epitope-specific responses to nucleoprotein and spike protein have contracted, and that responses to membrane protein have expanded. Although antibody titers to full-length spike and nucleoprotein remain steady over months, taken together our data suggest that the population of epitope-specific antibodies that contribute to this reactivity is dynamic and evolves over time. Further, the spike epitopes bound by polyclonal antibodies in COVID-19 convalescent serum samples aligned with known target sites that can neutralize viral activity suggesting that the maintenance of these antibodies might provide rapid serological immunity. Finally, the most dominant epitopes for membrane protein and spike showed high diagnostic accuracy providing novel biomarkers to refine blood-based antibody tests. This study provides new insights into the specific regions of SARS-CoV-2 targeted by serum antibodies long after infection.
Identifiants
pubmed: 35641545
doi: 10.1038/s41598-022-12032-8
pii: 10.1038/s41598-022-12032-8
pmc: PMC9152668
doi:
Substances chimiques
Antibodies, Viral
0
Coronavirus Nucleocapsid Proteins
0
Epitopes
0
Phosphoproteins
0
Spike Glycoprotein, Coronavirus
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9045Subventions
Organisme : CIHR
ID : OV5-170349
Pays : Canada
Informations de copyright
© 2022. The Author(s).
Références
EBioMedicine. 2020 Aug;58:102911
pubmed: 32711254
Cell Rep. 2021 Jan 26;34(4):108666
pubmed: 33503420
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
EClinicalMedicine. 2021 Feb;32:100734
pubmed: 33589882
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
PLoS One. 2021 Mar 4;16(3):e0247799
pubmed: 33662015
ACS Cent Sci. 2020 Dec 23;6(12):2238-2249
pubmed: 33372199
Science. 2021 Sep 03;373(6559):1109-1116
pubmed: 34344823
Cell. 2021 Mar 4;184(5):1201-1213.e14
pubmed: 33571429
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173
Viruses. 2021 Apr 10;13(4):
pubmed: 33920222
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Sci Immunol. 2021 Feb 23;6(56):
pubmed: 33622975
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
Sci Adv. 2021 Jan 1;7(1):
pubmed: 33277323
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Cell Mol Immunol. 2020 Oct;17(10):1095-1097
pubmed: 32895485
Science. 2020 Jun 12;368(6496):1274-1278
pubmed: 32404477
Emerg Microbes Infect. 2020 Dec;9(1):1988-1996
pubmed: 32844713
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Eur J Immunol. 2021 Jul;51(7):1839-1849
pubmed: 33772767
J Clin Immunol. 2021 Jul;41(5):906-913
pubmed: 33725211
Cell. 2021 Jun 10;184(12):3205-3221.e24
pubmed: 34015271
Cell Rep. 2021 Mar 30;34(13):108915
pubmed: 33761319
Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641
pubmed: 30976793
PLoS Pathog. 2021 Feb 26;17(2):e1009352
pubmed: 33635919
Cell Rep. 2021 May 25;35(8):109173
pubmed: 33991510
Nat Commun. 2020 Jun 1;11(1):2806
pubmed: 32483236
Immunol Rev. 2020 Jul;296(1):120-131
pubmed: 32483855